Detalhe da pesquisa
1.
Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
N Engl J Med
; 381(7): 614-625, 2019 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31050279
2.
Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study.
Mult Scler
; 28(6): 910-924, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34605319
3.
COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab.
Neurol Ther
; 11(2): 741-758, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35284994
4.
Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension.
Mult Scler Relat Disord
; 50: 102849, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33676197
5.
Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial.
Mult Scler Relat Disord
; 47: 102641, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33310418
6.
Leptomeningeal Contrast Enhancement Is Associated with Disability Progression and Grey Matter Atrophy in Multiple Sclerosis.
Neurol Res Int
; 2017: 8652463, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29291134
7.
Correction to: COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab.
Neurol Ther
; 11(2): 759-762, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35503396
8.
Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks.
Mult Scler Int
; 2016: 1034912, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-28078140